ArticleAnnals of medicine and surgery (2012)2026
From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial - a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Muhammad Qaseem et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.